Merck, Sharp & Dohme Inc. (MSD) (NYSE: MRK) reported third‑quarter 2026 worldwide revenue of USD 18.1 billion, up 5% year‑on‑year, supported by continued growth in oncology, vaccines, and newer product launches. The company narrowed its full‑year revenue guidance to USD 66.8–67.3 billion, raising the midpoint by USD 250 million.
Contents
Financial Milestone
| Item | Detail |
|---|---|
| Q3 2026 Worldwide Revenue | USD 18.1 bn, up 5% YoY |
| Global Pharmaceutical Revenue | USD 16.27 bn (+4%) |
| Animal Health Revenue | USD 1.68 bn (+4%) |
| FY2026 Revenue Guidance | Narrowed to USD 66.8–67.3 bn – midpoint raised USD 250 mn |
Franchise & Product Performance
| Product | Q3 2026 Sales | YoY Change | Notes |
|---|---|---|---|
| Keytruda (pembrolizumab) – incl. Keytruda Qlex subcutaneous formulation | USD 8.60 bn | +6% | Largest revenue contributor |
| Gardasil / Gardasil 9 | USD 2.0 bn | +14% | Driven primarily by stronger US demand; China sales remained limited |
| Winrevair (sotatercept) | USD 694 mn | +93% | Pulmonary arterial hypertension |
| Welireg (belzutifan) | USD 307 mn | +56% | Oncology |
| Capvaxive | USD 263 mn | Newer launch | Pneumococcal vaccine |
| Enflonsia (clesrovimab) | USD 187 mn | Recently launched | RSV antibody |
| Ohtuvayre (ensifentrine) | USD 184 mn | Acquired asset | Added via MSD’s 2025 acquisition of Verona Pharma |
| Januvia + Janumet | USD 380 mn combined | −39% | Generic competition in diabetes |
| Bridion (sugammadex) | USD 144 mn | −67% | Generic competition |
Geographic Revenue
| Region | Q3 2026 Revenue | YoY Change |
|---|---|---|
| United States | USD 10.62 bn | +6% |
| International (total) | USD 7.47 bn | +3% |
| Europe (pharmaceutical) | USD 2.84 bn | +6% |
| Japan | USD 569 mn | −18% |
| China (pharmaceutical) | USD 429 mn | +14% |
| Asia Pacific ex‑China/Japan | USD 596 mn | +1% |
| Latin America | USD 730 mn | +6% |
China – Sales Recover as Gardasil Pressures Persist
- Sequential Recovery: China pharmaceutical revenue increased 14% year‑on‑year to USD 429 million, recovering from USD 368 million in Q2; however, first‑nine‑month China sales of USD 1.15 billion remained 21% below the corresponding period of 2025.
- Gardasil Reset: The market continued to be affected by weaker Gardasil demand and elevated distributor inventories, which prompted MSD to suspend shipments to China in February 2025. Shipments resumed on a limited basis in Q2 2026 following a revised supply agreement with local partner Chongqing Zhifei Biological Products Co., Ltd., although MSD indicated that Gardasil revenue from China would remain immaterial in 2026.
- Oncology Drag: MSD also cited lower demand and pricing for Lynparza (olaparib) in China, contributing to a 7% decline in worldwide alliance revenue for the product to USD 352 million.
Market Impact & Outlook
- Guidance Confidence: Narrowing the outlook to USD 66.8–67.3 billion with a USD 250 million midpoint raise signals management conviction that oncology, vaccine, and launch‑portfolio momentum will carry through year‑end.
- Keytruda Durability: At USD 8.60 billion per quarter (+6%), including the newer subcutaneous Keytruda Qlex formulation, the franchise remains pharma’s largest product engine and extends the asset’s lifecycle.
- Launch Portfolio Scaling: Winrevair (+93%), Welireg (+56%), Capvaxive, Enflonsia, and Ohtuvayre now contribute meaningfully to growth, cushioning loss‑of‑exclusivity erosion.
- Generic Headwinds Contained: Combined declines in Januvia/Janumet (−39%) and Bridion (−67%) were more than absorbed by growth franchises.
- China Optionality Rebuilding: The 14% rebound in quarterly pharmaceutical revenue suggests stabilization, though the Gardasil franchise reset and Lynparza pricing pressure keep full recovery a multi‑quarter story.
- Japan Weakness: An 18% decline in Japan remains the quarter’s largest geographic headwind.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding MSD’s revenue guidance, product launches, China shipment resumption, and commercialization performance. Actual results may differ materially due to risks including generic competition, pricing and procurement pressures, distributor inventory normalization, foreign‑exchange fluctuations, and regulatory outcomes. Figures are as reported in the company’s Q3 2026 results.-Fineline Info & Tech
